Bangladesh - englanti - DGDA (Directorate General of Drug Administration)

beximco pharmaceuticals ltd. - fluticasone furoate + umeclidinium + vilanterol - dry powder inhaler - 200 mcg + 62.5 mcg + 25 mcg

Bangladesh - englanti - DGDA (Directorate General of Drug Administration)

aristopharma limited - fluticasone furoate + umeclidinium + vilanterol - dry powder inhaler - 100 mcg + 62.5 mcg + 25 mcg

Bangladesh - englanti - DGDA (Directorate General of Drug Administration)

healthcare pharmaceuticals ltd. - fluticasone furoate + umeclidinium + vilanterol - dry powder inhaler - 100 mcg + 62.5 mcg + 25 mcg

Australia - englanti - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - salmeterol xinafoate, quantity: 36.32 microgram/actuation (equivalent: salmeterol, qty 25 microgram/actuation); fluticasone propionate, quantity: 250 microgram/actuation - inhalation, pressurised - excipient ingredients: norflurane - for the regular treatment of asthma, where the use of a combination product is appropriate. this may include: - patients on effective maintenance doses of long-acting beta-2 agonists and inhaled corticosteroids. - patients who are symptomatic on current inhaled corticosteroid therapy.,for the symptomatic treatment of patients with severe copd (fev1 less than 50 precent predicted normal) and a history of repeated exacerbations who have significant symptoms despite regular beta-2 agonist bronchodilator therapy. fluticasone propionate/salmeterol (125 microgram/25 microgram and 250 microgram/25 microgram) is not indicated for the initiation of bronchodilator therapy in copd.

Australia - englanti - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - salmeterol xinafoate, quantity: 36.32 microgram/actuation (equivalent: salmeterol, qty 25 microgram/actuation); fluticasone propionate, quantity: 125 microgram/actuation - inhalation, pressurised - excipient ingredients: norflurane - for the regular treatment of asthma, where the use of a combination product is appropriate. this may include: - patients on effective maintenance doses of long-acting beta-2 agonists and inhaled corticosteroids. - patients who are symptomatic on current inhaled corticosteroid therapy.,for the symptomatic treatment of patients with severe copd (fev1 less than 50 precent predicted normal) and a history of repeated exacerbations who have significant symptoms despite regular beta-2 agonist bronchodilator therapy. fluticasone propionate/salmeterol (125 microgram/25 microgram and 250 microgram/25 microgram) is not indicated for the initiation of bronchodilator therapy in copd.

Euroopan unioni - englanti - EMA (European Medicines Agency)

glaxosmithkline (ireland) limited - fluticasone furoate, vilanterol - pulmonary disease, chronic obstructive - adrenergics and other drugs for obstructive airway diseases - asthma indication:relvar ellipta is indicated in the regular treatment of asthma in adults and adolescents aged 12 years and older, where use of a combination product (long-acting beta2-agonist and inhaled corticosteroid) is appropriate:patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short acting beta2-agonists.patients already adequately controlled on both inhaled corticosteroid and long-acting beta2-agonist.copd indication:relvar ellipta is indicated for the symptomatic treatment of adults with copd with a fev1

Euroopan unioni - englanti - EMA (European Medicines Agency)

glaxosmithkline (ireland) limited - fluticasone furoate, vilanterol trifenatate - asthma - adrenergics and other drugs for obstructive airway diseases - asthma indicationrevinty ellipta is indicated in the regular treatment of asthma in adults and adolescents aged 12 years and older, where use of a combination product (long-acting beta2-agonist and inhaled corticosteroid) is appropriate:patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short acting beta2-agonists.copd indicationrevinty ellipta is indicated for the symptomatic treatment of adults with copd with a fev1

Euroopan unioni - englanti - EMA (European Medicines Agency)

glaxosmithkline (ireland) limited - fluticasone furoate - rhinitis, allergic, seasonal; rhinitis, allergic, perennial - nasal preparations, corticosteroids - adults, adolescents (12 years and over) and children (6-11 years). avamys is indicated for the treatment of the symptoms of allergic rhinitis.

Yhdysvallat - englanti - NLM (National Library of Medicine)

unit dose services - fluticasone propionate (unii: o2gmz0lf5w) (fluticasone - unii:cut2w21n7u) - fluticasone propionate 50 ug - fluticasone propionate nasal spray, usp 50 mcg per spray is indicated for the management of the nasal symptoms of perennial nonallergic rhinitis in adult and pediatric patients aged 4 years and older. fluticasone propionate nasal spray is contraindicated in patients with hypersensitivity to any of its ingredients [see warnings and precautions (5.3), description (11)]. teratogenic effects pregnancy category c. there are no adequate and well-controlled trials with fluticasone propionate nasal spray in pregnant women. corticosteroids have been shown to be teratogenic in laboratory animals when administered systemically at relatively low dosage levels. because animal reproduction studies are not always predictive of human response, fluticasone propionate nasal spray should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. women should be advised to contact their physicians if they become pregnant while taking fluticasone propionate nasal spray. mice and rats at flut

Yhdysvallat - englanti - NLM (National Library of Medicine)

unit dose services - fluticasone propionate (unii: o2gmz0lf5w) (fluticasone - unii:cut2w21n7u) - fluticasone propionate 50 ug in 0.1 g - fluticasone propionate nasal spray, usp, is indicated for the management of the nasal symptoms of seasonal and perennial allergic and nonallergic rhinitis in adults and pediatric patients 4 years of age and older. safety and effectiveness of fluticasone propionate nasal spray, usp, in children below 4 years of age have not been adequately established. fluticasone propionate nasal spray, usp, is contraindicated in patients with a hypersensitivity to any of its ingredients. please read this leaflet carefully before you start to take your medicine. it provides a summary of information on your medicine. for further information ask your doctor or pharmacist. rhinitis is a word that means inflammation of the lining of the nose. if you suffer from rhinitis, your nose becomes stuffy and runny. rhinitis can also make your nose itchy, and you may sneeze a lot. rhinitis can be caused by allergies to pollen, animals, molds, or other materials-or it may have a nonallergic cause. your doctor has